A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
Phase of Trial: Phase II
Latest Information Update: 23 May 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Ribociclib (Primary)
- Indications Duodenal cancer; Gastric cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 19 Dec 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
- 19 Dec 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
- 27 Feb 2018 Last checked against Clinicaltrials.gov record.